The European Vascular Biology Institute (EVBI) is being presented at the annual EuroBioForum conference in Lisbon in December 2007 with a specific brief to convert research into concrete therapies more effectively. EuroBioForum is the annual conference of EuroBioFund, which was established in 2006 to bring together public and private sources of funding to catalyse the development of large scale pan-European life science research programmes. EVBI is one of several major themes being presented at EuroBioForum this year.
The EVBI aims to make another dramatic advance in the fight against cardiovascular disease. Although great progress has been made in recent decades with drugs such as angiotensin converting enzyme inhibitors that reduce blood pressure and statins that reduce cholesterol levels, more sophisticated therapies acting directly at the molecular level are needed to take a further major step forward. The aim is to develop a new generation of drugs that are highly specific in their action.
The EVBI will focus strongly on atherosclerosis, according to one of the institute's main proposers Alain Tedgui, because this is the underlying cause of 80% of all cardiovascular related deaths including myocardial infarction (heart attacks) and strokes, as well as other conditions such as tissue death and organ failure. It occurs to varying degrees in all humans, being a chronic inflammatory disease of the arteries in which atherosclerotic plaques develop, leading ultimately to a variety of complications including blood clotting and loss of blood supply to organs. The EVBI aims both to block progress of atherosclerosis through drug therapies and vaccination, and also to tackle the related diseases, for example via stem cell based therapies to repair the heart after myocardial infarction.
Fortunately the EVBI does not have to start from a clean slate, but proposes to build on existing projects, and in particular the European Vascular Genomics Network (EVGN), which has been running since January 2004 as part of the European Commission's FP6 framework research programme. EVGN has been promoting multidisciplinary interaction between 30 world class basic and clinical institutions in 11 European countries. The EVBI will harness this work. "The EVBI sets a milestone for our perpetuation strategy," said Catherine Clusel, the Project Manager of EVGN. This is also where the EuroBioFund comes in, Clusel added. "It will allow us to present the existing framework to potential funders, including on one side the pharmaceutical companies involved in the elaboration of the Strategic Research Agenda (SRA) for the Innovative Medicines Initiative, and on the other side the European public or private foundations that are eager to support the most prestigious high profile research groups working in this area in Europe. EVBI addresses bottlenecks identified within the SRA for safety and efficacy in inflammatory diseases with an emphasis on atherosclerosis, and unites the European key opinion leaders in cardiovascular disease."
On the scientific front, EVBI will exploit existing project platforms, notably the EVGN's Zebrafish animal model, which allows vascular disease progression and the action of therapies to be monitored and analysed closely. The aim is to build on these platforms within an integrated and ongoing programme, said Clusel, providing secure long lasting funding with the aim of keeping Europe at the forefront of this crucial area of medical research.
Thomas Lau | alfa
The genes are not to blame
20.07.2018 | Technische Universität München
Targeting headaches and tumors with nano-submarines
20.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz
A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.
The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...
For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.
To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...
For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.
Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...
Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.
A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...
Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.
"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....
13.07.2018 | Event News
12.07.2018 | Event News
03.07.2018 | Event News
20.07.2018 | Power and Electrical Engineering
20.07.2018 | Information Technology
20.07.2018 | Materials Sciences